Generic Name and Formulations:
Drospirenone 3mg, ethinyl estradiol 30micrograms (21 tabs); inert (7 tabs).
Indications for SYEDA:
1 tab daily for 28 days; repeat.
Thrombophlebitis or thromboembolic disorders. Cerebral vascular or coronary artery disease. Breast or other estrogen-dependent neoplasms. Undiagnosed abnormal genital bleeding. Renal, hepatic, or adrenal insufficiency. Cholestatic jaundice of pregnancy or jaundice with prior OC use. Hepatic adenoma or carcinoma. Pregnancy (Cat.X).
Hypertriglyceridemia. Discontinue if jaundice, visual disturbances, migraine or other severe headaches occur. Do regular complete physical exams. May need barrier contraception with Sunday starts or postpartum use (see literature). Monitor K+ during 1st cycle if risk of hyperkalemia. Nursing mothers: not recommended.
Antagonized by hepatic enzyme inducing drugs (eg, rifampin, griseofulvin, St. John's wort), possibly others. May affect measurement of sex hormone-binding globulin levels. Monitor K+ during 1st cycle with drugs that increase potassium (eg, ACE inhibitors, angiotensin receptor blockers, NSAIDs, K+ sparing diuretics).
Progestin + estrogen.
Hypertension, nausea, vomiting, breakthrough bleeding, amenorrhea, transient delay of ovulation after discontinuation, edema, chloasma, mastodynia, headache, intolerance to contact lenses. Increased risk of gallbladder disease, thromboembolic disorders.
- 28 tablets of 3mg/0.03mg packages (Qty:1)
- appx. price $105.00
- Nine Factors That Appear to Elevate Alzheimer's Risk
- NSAIDs Linked to Long-Term Colon Cancer Risk Reduction
- Clinical Suspicion Leads to Uncommon Diagnosis in Patient With High Fever
- Doctors Behaving Badly: Anonymous Essay Reveals Shocking Behaviors
- What a New Study Says About Omega-3s and Brain Health